Screener
Kymera Therapeutics KYMR Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
FAQ
- What is Kymera Therapeutics's free cash flow?
- Kymera Therapeutics (KYMR) reported free cash flow of -$54.54M in Q2 2026.
- How has Kymera Therapeutics's free cash flow changed year-over-year?
- Kymera Therapeutics's free cash flow increased by 10.0% year-over-year, from -$60.58M to -$54.54M.
- What is the long-term trend for Kymera Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Kymera Therapeutics's free cash flow has grown at a 15.8% compound annual growth rate (CAGR), from -$130.54M to -$234.34M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Kymera Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude